On September 18, Sichuan Provincial People’s Government issued the “Decision of Sichuan Provincial People’s Government on the Awarding of Sichuan Patent Award in 2022” (Chuan Fu Fa [2023] 22). Guorui Pharmaceutical, a subsidiary of BIOKIN PHARMACEUTICAL, won the Sichuan Patent Award—Innovation and Entrepreneurship Award for the invention patent titled “A Preparation Method of High Purity Propofol”.       

The Sichuan Patent Award is the highest patent award in Sichuan Province established by Sichuan Provincial People's Government. Awarded once a year, it is a financial incentive for patents with stable patent rights, a high level of creation, good implementation efficiency and strong protection ability. The Sichuan Patent Award—Innovation and Entrepreneurship Award is an award for patents which have a more innovative technology solution compared with the prior art, have been successfully implemented, and have achieved good economic and social benefits, good development prospect and growth of the patented technology or product.

The Company always attaches importance to the creation and protection of intellectual property rights, and the core member of the Group, BIOKIN PHARMACEUTICAL, is a state-level demonstration enterprise with intellectual property advantages. As of June 30, 2023, the Group had obtained a total of 91 invention patents (53 domestic and 38 overseas). The implemented patents have provided a strong technical support for the Group in marketing chemical drugs and traditional Chinese medicine products, and is an important guarantee for the Company's product market competitiveness. Especially since the innovation transformation began in 2011, the Company has accelerated the patent fence layout of core patents. Centering on the core technology, the Company has applied for more than 400 invention patents in 16 countries or regions around the world (including the European Union).